To capture low-IRT CF cases that evade detection, we have had discussions with other NBS programs in the United States about whether to collect risk factors for CF—such as meconium ileus at birth or maternal CFTR modulator drug exposure during pregnancy—on the bloodspot test request form to initiate molecular testing for CF regardless of IRT result when a risk factor is noted. The gene discussed is CFTR; the disease is intestinal obstruction in the newborn due to guanylate cyclase 2C deficiency.